Duchenne muscular dystrophy newborn screening: the first 50,000 newborns screened in Taiwan

Yin-Hsiu Chien1,2,3 · Ni-Chung Lee1,2,3 · Wen-Chin Weng2,3 · Li-Chu Chen1 · Yu-Hsuan Huang1 · Chao-Szu Wu1 · Wuh-Liang Hwu1,2,3

Received: 21 March 2022 / Accepted: 4 May 2022 / Published online: 13 May 2022 © The Author(s) 2022

Abstract
Background Duchenne muscular dystrophy (DMD/Duchenne) is a progressive X-linked muscular disease with an overall incidence of 1:5,000 live male births. Recent availability in treatment for DMD raised the need of early diagnosis, and DMD became as a selective item of newborn screening (NBS) since Feb. 2021 in our center.

Materials and methods Dried blood spots (DBS) muscle-type creatine kinase (CK) isoform was measured with a commercialized kit with age-adjusted cutoffs. Subjects with an elevation of CK in the first screen were requested for a re-screen 2 weeks later. A DBS whole-exome sequencing (WES) panel for dystrophin and other neuromuscular-related genes was applied to confirm the diagnosis for subjects with persistent hyperCKemia.

Results During a 1-year period, 50,572 newborns (male 26,130) received DMD screening at a mean age of 2 days (SD 1 day). Among them, 632 (1.2%) had an elevated CK value. A re-screen at a mean age of 14 days (SD 8 days) revealed 14 subjects with persistent hyperCKemia, and DMD was confirmed in 3 of them. The incidence of DMD in Taiwan was 1:8,710 (95% CI 1 in 2,963 to 1 in 25,610) live birth males. Results of DMD DBS also assisted in Pompe newborn screening.

Conclusions NBS for DMD enables earlier management of the disease. The high re-screening rate could potentially be waived by moving the DBS WES assay to a second-tier test. The long-term benefit and the impact of newborn screening on the prognosis of DMD, however, remain further elucidated.

Keywords Duchenne muscular dystrophy (DMD) · Creatine kinase (CK) · Whole-exome sequencing (WES) · Newborn screening (NBS)

Introduction
Duchenne muscular dystrophy (DMD) is an X-linked muscular degenerative disorder, leading to wheelchair confinement at 8–12 years of age and the associated cardiomyopathy, with an incidence of 1:3,600–9,300 live male births [1]. Despite advances and increased availability of genetic testing for DMD, the mean age at diagnosis is 3.5–5 years, usually up to 2 years later than the appearance of first symptoms. New treatments for DMD are also developing, including reading-through [2], exon-skipping, and gene therapy [3].

Newborn screening (NBS) for DMD by measuring creatine kinase (CK) activity has been attempted for a few years; however, a high false-positive rate was reported in all programs; therefore, variable strategies including re-screen and molecular testing have been employed [4–6]. We have added DMD NBS into our routine NBS program since 2021. Here, we report our screening strategy and results of the first year of universal, population-based screening in 50,000 newborns.

Materials and methods
The NBS Center at the National Taiwan University Hospital (NTUH) conducts routine newborn screening for approximately 35% born babies around Taiwan. DBS samples were
obtained at 48–72 h after birth. DBS CK-MM was measured using a GSP® Neonatal Creatine Kinase-MM kit with a fully automated GSP instrument (both manufactured by PerkinElmer, Turku, Finland) according to the manufacturer’s instruction. Newborns who had a first-screen CK-MM level higher than cutoffs (the 99th percentile of normal newborns, 750 ng/mL whole blood (WB) in full term babies and 650 ng/mL in premature babies) were requested to have a re-screen 2 weeks later. The cutoff for re-screen was 300 ng/mL. For those with an elevated CK-MM level at re-screen, defined as persistent hyperCKemia, a 3rd CK-MM measurement and molecular analysis were requested. The molecular analysis was performed on DNA extracted from DBS using a whole-exome sequencing (WES) muscle panel for the targeted DMD gene and other neuromuscular related genes.

Results

Between Feb. 2021 and Dec. 2021, 50,572 newborns were screened with the CK-MM assay at a mean age of 3 days (SD 3 days). In total, 1.2% (632) of the newborns displayed an elevation in CK-MM in their first samples collected at a mean age of 2 days (SD 1 day), slightly earlier than the population’s practice. Among them, 510 (81%) re-call samples were tested at the mean age of 12 days (SD 8 days) and were returned to normal CK-MM levels. Five subjects (1%) had died of unrelated reasons and were not able to have another check. Four subjects (one female and three males) were unable to do the re-screen, and WES using the first-screen DBS revealed a variant on COL12A1 gene in a male subject. Fourteen newborns (2%) met the criteria of persistent hyperCKemia, but eleven (7 males and 4 females) of the 14 newborns had normal CK-MM levels in their 3rd samples. Molecular tests in the remaining 3 subjects with persistent hyperCKemia confirmed as having variants on DMD gene (Fig. 1) in all of them. The first CK-MM values for cases 1, 2, and 3 were 5247, 15983, and 15104 ng/mL, respectively. The 2nd CK-MM values were 1885, 3058, and 4403 ng/mL, respectively. Finally, the serum CK levels as the confirmatory tests were 4070, 5337, and 3457 U/L, respectively.

Two subjects (cases 1 and 2), one with an approximately 600-bp deletion involving exon 20 of the DMD gene and the other involving 8 exons deletion from exon 44 to exon 51, inherited the deletion from the mothers, but no other affected individuals known in the families. The third subject had a single nucleotide variation c.9337C>T (p.R3113*), which should cause a premature termination of the transcript. Overall, the incidence of DMD derived from the current study was 1:8,710 (95% CI 1 in 2,963 to 1 in 25,610) live birth males. Case 1 showed a borderline below gross motor performance quotient at age 6 months, and the use of Deflazacort was under discussion.

We hypothesized that first-screen CK-MM levels could help make the clinical judgement of babies with acid alpha-glucosidase (GAA) deficiency or Pompe disease. GAA deficiency was defined as lymphocyte GAA activity <3% of the normal mean and GAA variants on both the maternally and paternally inherited chromosomes; infantile-onset Pompe disease (IOPD) refers to patients with cardiac involvement at the time of diagnosis, and all other cases are classified as later-onset Pompe disease and were followed for symptoms as previously reported [7]. In this period, we encountered 13 subjects with positive Pompe NBS, with 5 GAA deficiency and 8 partial GAA deficiency. Among them, only 1 newborn with CK-MM at 470 ng/mL (Fig. 1 and 2), approximately at the 95th percentile of the newborn range, had the lowest GAA activity in DBS, and was confirmed as a patient with classical IOPD due to the presence of hypertrophic cardiomyopathy. We have initiated the disease-specific treatment at the age of 9 days. The 2nd highest CK-MM, 375 ng/mL, was approximately at the 90th percentile and was found in a newborn diagnosed with later-onset Pompe disease. The other 3 newborns with later-onset Pompe disease and the other 8 newborns with partial GAA deficiency had normal CK-MM levels. None of the 4 subjects with later-onset Pompe disease has been on treatment yet. During this period, we did not encounter newborns who were positive for spinal muscular atrophy (SMA) screening; therefore, there was no information about the utility of CK-MM assay in SMA NBS.
Fig. 2 DBS CK-MM levels in subjects with positive Pompe disease screening. In total, 13 newborns showed low in acid alpha glucosidase (GAA) in the dried blood spots (DBS), defined as positive in Pompe newborn screening, were plotted. The one with infantile-onset Pompe disease (IOPD) had the lowest DBS GAA activity, and a high CK-MM level at the 95th percentile (blue dash line). Only one of the four newborns (NBSL) with GAA deficiency but no cardiomyopathy, defining as later-onset Pompe disease, had a CK-MM levels at the 90th percentile. All the others (partial GAA deficiency), although low in DBS GAA activity, were diagnosed as partial GAA deficiency by their genotypes and lymphocytes GAA activities and they all have quite normal DBS CK-MM levels.

Discussion

Here we reported a universal NBS for DMD using a FDA-approved immunoassay. In contrast to a re-screen rate of 0.9% (237 out of the 26,135 newborns) in the New York State (NYS) Newborn Screening Program [8], we experienced a high intended re-screen rate (1.2%), in order not to have false negatives as in the Wales program [9] or miss boys with a Becker muscular dystrophy phenotype [4, 5]. Most subjects have normal CK-MM levels at the second screen at 2 weeks of age, because the CK-MM levels indeed stabilized at 1 week of life [8]. We could improve the specificity of DMD NBS by adding a 2nd-tier WES test when the original samples revealed high CK-MM [5, 10]; this will be especially benefit to those who were not able to have a 2nd sample, say, in the period of COVID-19 pandemic as in our current report, and to whom had excessive stress facing the potential false-positive results. However, the add-on cost was not acceptable in our current program and was not executed yet.

In the current report, we identified newborns with DMD in one out of 8,710 live male newborns. Recent advances such as the increased disease awareness, uptake of expanded carrier screening, and the usage of advanced prenatal testing all should have an impact to the nature occur incidence of DMD. Nevertheless, one recent genotype study in Taiwan showed that only 50% of DMD cases could be detected by multiplex ligation-dependent probe amplification (MLPA) [11], implying the limitation of current carrier or prenatal DMD screening. NBS using a biochemical marker will be necessary for early diagnosis of DMD.

DMD NBS process additional utilities as demonstrated in our report. Since other diseases with the associated CK-MM elevations may be revealed by this, it is useful to conjunction DBS CK-MM to other screening such as Pompe NBS to help the identification of IOPD so that treatment can be start immediately. Only patients with IOPD, but not LOPD, will have the elevation in CK-MM at the first screening sample.

A clear guideline for prospectively followed asymptomatic DMD patients on when and how to initiate treatment is not available yet. Most of the clinical trials for new treatment were conducted in patients aged 4 years or older, even though patients may present with gross motor delay from 4 to 4 months of age [12]. For the use of glucocorticosteroids, only Deflazacort has been approved for patients aged 2 years and older. Long-term outcome data generated from newborn screening will certainly be critical to make a guideline for pre-symptomatic follow-up of DMD.

Declarations

Informed consent None.

Ethical approval This study was approved by the institutional review board of the NTUH (NTUH-IRB; No. 201105033RB) and informed consent was waived.

Conflict of Interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Mah JK, Korngut L, Dykeman J, Day L, Pringsheim T, Jette N (2014) A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul Disord 24(6):482–491. https://doi.org/10.1016/j.nmd.2014.03.008
2. Politano L (2021) Read-through approach for stop mutations in Duchenne muscular dystrophy. An update. Acta Myol 40(1):43–50. https://doi.org/10.36185/2532-1900-041
3. Vita G, Vita GL, Musumeci O, Rodolico C, Messina S (2019) Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and
skeletal muscle. Neurol Sci 40(4):671–681. https://doi.org/10.1007/s10072-019-03764-z

4. Gatheridge MA, Kwon JM, Mendell JM, Scheuerbrandt G, Moat SJ, Eyskens F et al (2016) Identifying non-Duchenne muscular dystrophy-positive and false negative results in prior duchenne muscular dystrophy newborn screening programs: a review. JAMA Neurol 73(1):111–116. https://doi.org/10.1001/jamaneurol.2015.3537

5. Mendell JR, Shilling C, Leslie ND, Flanigan KM, al Dahhak R, Gastier-Foster J et al (2012) Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 71(3):304–313. https://doi.org/10.1002/ana.23528

6. Nallamilli BRR, Chaubey A, Valencia CA, Stansberry L, Behlmann AM, Ma Z et al (2021) A single NGS-based assay covering the entire genomic sequence of the DMD gene facilitates diagnostic and newborn screening confirmatory testing. Hum Mutat 42(5):626–638. https://doi.org/10.1002/humu.24191

7. Lee NC, Chang KL, In’t Groen SLM, de Faria DOS, Huang HJ, Pijnappel W et al (2022) Outcome of later-onset Pompe disease identified through newborn screening. J Pediatr. https://doi.org/10.1016/j.jpeds.2021.12.072

8. Park S, Maloney B, Caggana M, Tavakoli NP (2022) Creatine kinase-MM concentration in dried blood spots from newborns and implications for newborn screening for Duchenne muscular dystrophy. Muscle Nerve. https://doi.org/10.1002/mus.27533

9. Moat SJ, Bradley DM, Salmon R, Clarke A, Hartley L (2013) Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK). Eur J Hum Genet 21(10):1049–1053. https://doi.org/10.1038/ejhg.2012.301

10. Wang LY, Chen NI, Chen PW, Chiang SC, Hwu WL, Lee NC et al (2013) Newborn screening for citrin deficiency and carnitine uptake defect using second-tier molecular tests. BMC Med Genet 14:24. https://doi.org/10.1186/1471-2350-14-24

11. Liang WC, Wang CH, Chou PC, Chen WZ, Jong YJ (2018) The natural history of the patients with Duchenne muscular dystrophy in Taiwan: a medical center experience. Pediatr Neonatol 59(2):176–183. https://doi.org/10.1016/j.pedneo.2017.02.004

12. Connolly AM, Florence JM, Cradock MM, Malkus EC, Schierbecker JR, Siener CA et al (2013) Motor and cognitive assessment of infants and young boys with Duchenne muscular dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network. Neuromuscul Disord 23(7):529–539. https://doi.org/10.1016/j.nmd.2013.04.005

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.